CR10873A - Composiciones farmaceuticas y sus metodos de uso - Google Patents

Composiciones farmaceuticas y sus metodos de uso

Info

Publication number
CR10873A
CR10873A CR10873A CR10873A CR10873A CR 10873 A CR10873 A CR 10873A CR 10873 A CR10873 A CR 10873A CR 10873 A CR10873 A CR 10873A CR 10873 A CR10873 A CR 10873A
Authority
CR
Costa Rica
Prior art keywords
methods
pharmaceutical compositions
ligand
manufacture
positive
Prior art date
Application number
CR10873A
Other languages
English (en)
Inventor
Murali Gopalakrishnan
Marie P Honore
Chih-Hung Lee
John Malysz
Jianguo Ji
Tao Li
Michael R Schrimpf
Kevin B Sippy
David J Anderson
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CR10873A publication Critical patent/CR10873A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Una composicion que comprende un ligando de un receptor nicotinico neuronal y un modulador alosterico positivo de 4 2, un metodo para usarla y un articulo de manufactura relacionado.
CR10873A 2006-12-12 2009-06-19 Composiciones farmaceuticas y sus metodos de uso CR10873A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87460906P 2006-12-12 2006-12-12
US99976107P 2007-04-12 2007-04-12
US11/953,625 US20080167286A1 (en) 2006-12-12 2007-12-10 Pharmaceutical compositions and their methods of use

Publications (1)

Publication Number Publication Date
CR10873A true CR10873A (es) 2009-07-23

Family

ID=39427547

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10873A CR10873A (es) 2006-12-12 2009-06-19 Composiciones farmaceuticas y sus metodos de uso

Country Status (16)

Country Link
US (3) US20080167286A1 (es)
EP (3) EP2226074B1 (es)
JP (1) JP2010512419A (es)
KR (1) KR20090098884A (es)
AU (1) AU2007333129A1 (es)
BR (1) BRPI0720124A2 (es)
CA (1) CA2671683A1 (es)
CO (1) CO6210820A2 (es)
CR (1) CR10873A (es)
DO (1) DOP2009000137A (es)
EC (1) ECSP099495A (es)
ES (2) ES2558054T3 (es)
MX (1) MX2009006235A (es)
NO (1) NO20092584L (es)
TW (1) TW200901995A (es)
WO (1) WO2008073942A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777663A (en) * 1986-08-08 1988-10-11 Corning Glass Works Data rate limiter for optical transmission system
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
IL169855A (en) * 2005-07-25 2014-05-28 Elta Systems Ltd A system and method for locating a receiver location
CA2616377C (en) 2005-07-26 2014-04-01 David Alexander Learmonth Nitrocatechol derivatives as comt inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2133337A1 (en) 2006-05-09 2009-12-16 AstraZeneca AB Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
CN101562977A (zh) 2006-12-15 2009-10-21 艾博特公司 新的二唑化合物
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
EP2481410B1 (en) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
CA2696609C (en) 2007-08-27 2017-09-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
NZ586651A (en) * 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
ES2455197T3 (es) 2007-12-07 2014-04-14 Abbvie Deutschland Gmbh & Co Kg Derivados de oxindol 5,6-disustituidos y el uso de los mismos para la preparación de un medicamento para el tratamiento de enfermedades dependientes de vasopresina
US8703775B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
WO2010009775A1 (de) * 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
TW200942531A (en) 2008-03-17 2009-10-16 Bial Portela & Companhia S A Crystal forms of a nitrocatechol
JP2011522818A (ja) * 2008-06-06 2011-08-04 アボット・ラボラトリーズ 新規１，２，４オキサジアゾール化合物およびこれらの使用方法
EP2344484B1 (en) 2008-10-17 2016-06-08 Akaal Pharma Pty Ltd S1p receptors modulators and use thereof
US9181182B2 (en) 2008-10-17 2015-11-10 Akaal Pharma Pty Ltd S1P receptors modulators
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
WO2010080757A2 (en) * 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
KR20210009441A (ko) 2009-04-01 2021-01-26 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
EP2435080A2 (en) * 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
CN102573478B (zh) * 2009-10-12 2015-12-16 拜尔农作物科学股份公司 作为杀虫剂的1-(吡啶-3-基)-吡唑和1-(嘧啶-5-基)-吡唑
US8461171B2 (en) * 2010-02-09 2013-06-11 QRxPharma Ltd. Hybrid opioid compounds and compositions
AU2011256866B2 (en) 2010-05-20 2014-05-22 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
JP5681819B2 (ja) 2011-02-11 2015-03-11 バットマーク・リミテッド 吸入器コンポーネント
ME02107B (me) * 2011-09-19 2015-10-20 Heteroaril jedinjenja kao ligandi 5-ht4 receptora
IN2014MN00714A (es) * 2011-10-20 2015-07-03 Chromocell Corp
PT2791134T (pt) 2011-12-13 2019-12-18 BIAL PORTELA & Cª S A Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
AU2014257086A1 (en) 2013-04-24 2015-11-12 Chromocell Corporation Assays for identifying compounds that modulate bitter taste
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
CA2981066A1 (en) * 2015-03-31 2016-10-06 Monsanto Technology Llc Processes for the preparation of 2-thiophenecarbonyl chloride
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
WO2017165356A1 (en) 2016-03-24 2017-09-28 Monsanto Technology Llc Processes for the preparation of heteroaryl carboxylic acids
WO2018187479A1 (en) * 2017-04-04 2018-10-11 Case Western Reserve University Method of modulating ribonucleotide reductase

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2950707A (en) 1959-10-13 1960-08-30 Butler Frank David Combined liquid fuel and excess air metering and distributing, combined liquid fuel and excess air atomizing and injecting, internal combustion engine
US3964896A (en) * 1971-08-09 1976-06-22 Uniroyal, Inc. Oxadiazole benzoic acid derivatives as herbicides
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
CH623971B5 (de) * 1976-06-04 1982-01-15 Hoechst Ag Verfahren zur herstellung neuer benzofuranderivate und deren verwendung als optische aufheller.
JPH07502529A (ja) 1991-12-31 1995-03-16 藤沢薬品工業株式会社 アセチルコリンエステラーゼ阻害およびムスカリン様のアゴニスト活性を有するオキサジアゾール誘導体
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5948793A (en) * 1992-10-09 1999-09-07 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
US5914328A (en) * 1992-10-09 1999-06-22 Abbott Laboratories Heterocyclic ether compounds useful in controlling neurotransmitter release
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
ES2221234T3 (es) 1997-12-19 2004-12-16 Abbott Laboratories Compuestos de eter y tioeter heterociclicos utilizados en la regulacion de la transmision sinaptica quimica.
US6605610B1 (en) 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
JP4240815B2 (ja) 1998-06-16 2009-03-18 ターガセプト，インコーポレイテッド アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6207863B1 (en) * 1998-08-11 2001-03-27 Rohm And Haas Company Synthesis of haloformimine compounds
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
PL200427B1 (pl) 1999-05-21 2009-01-30 Abbott Lab Związek aminoazacykliczny, kompozycja farmaceutyczna go zawierająca i jego zastosowanie
US6833370B1 (en) * 1999-05-21 2004-12-21 Abbott Laboratories Heterocycle substituted aminoazacycles useful as central nervous system agents
EP1185514A1 (en) 1999-06-07 2002-03-13 Targacept, Inc. Pharmaceutical compositions and methods for use
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805536B1 (fr) 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
JP2001302643A (ja) 2000-04-21 2001-10-31 Suntory Ltd 環状アミジン化合物
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
US6809105B2 (en) * 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
FR2810320B1 (fr) * 2000-06-19 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
KR100838447B1 (ko) 2001-02-21 2008-06-16 아스트라제네카 아베 헤테로폴리시클릭 화합물 및 대사향성 글루타메이트수용체 길항제로서의 그의 용도
KR20040004705A (ko) 2001-06-08 2004-01-13 시토비아 인크. 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
MXPA04004464A (es) * 2001-11-08 2004-08-11 Upjohn Co Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
US7135484B2 (en) * 2002-08-14 2006-11-14 Abbott Laboratories Azabicyclic compounds are central nervous system active agents
EP1530624A2 (en) * 2002-08-20 2005-05-18 The Procter & Gamble Company Method for maufacturing liquid gel automatic dishwashing detergent compositions comprising anhydrous solvent
EP3345895B1 (en) * 2003-04-11 2019-12-04 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2005034952A2 (en) * 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
DE102004033834A1 (de) 2004-07-13 2006-02-02 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
NZ553329A (en) * 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
US20060252786A1 (en) * 2004-10-21 2006-11-09 The Trustees Of Columbia University Nicotinic-opioid synergy for analgesia
US8378109B2 (en) * 2004-12-07 2013-02-19 The Regents Of The University Of California Labeled ALPHA4BETA2 ligands and methods therefor
JP2008525524A (ja) 2004-12-28 2008-07-17 アストラゼネカ・アクチエボラーグ アリールスルホンアミドモジュレーター
JP2008526702A (ja) 2004-12-31 2008-07-24 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体、該誘導体を含んでいる薬物及びそれらの使用
US8030499B2 (en) * 2005-01-28 2011-10-04 Taisho Pharmaceutical Co., Ltd. 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
US7019503B1 (en) 2005-02-07 2006-03-28 Raytheon Company Active power filter with input voltage feedforward, output load feedforward, and output voltage feedforward
US20080261999A1 (en) * 2005-03-04 2008-10-23 Fionna Mitchell Martin Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists
CA2602194A1 (en) 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
DE102005014904A1 (de) 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014936A1 (de) * 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
EP1881979B1 (en) * 2005-04-26 2010-08-11 NeuroSearch A/S Novel oxadiazole derivatives and their medical use
US20070184490A1 (en) * 2006-01-17 2007-08-09 Marleen Verlinden Neuronal nicotinic receptor ligands and their use
US20080015193A1 (en) 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
EP2255848A3 (en) 2006-09-04 2011-04-06 NeuroSearch AS Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
PT2114921E (pt) 2006-12-30 2013-03-26 Abbott Gmbh & Co Kg Derivado de oxindol substituído e sua utilização como ligante do recetor de vasopressina
EP2114922B1 (en) 2006-12-30 2013-04-24 Abbott GmbH & Co. KG Substituted oxindole derivative and its use as a vasopressin receptor modulator
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2008080971A1 (en) 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Substituted oxindole derivative and its use as a vasopressin receptor ligand
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US8703775B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
NZ586651A (en) 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
ES2455197T3 (es) 2007-12-07 2014-04-14 Abbvie Deutschland Gmbh & Co Kg Derivados de oxindol 5,6-disustituidos y el uso de los mismos para la preparación de un medicamento para el tratamiento de enfermedades dependientes de vasopresina
JP2011522818A (ja) 2008-06-06 2011-08-04 アボット・ラボラトリーズ 新規１，２，４オキサジアゾール化合物およびこれらの使用方法
EP2435080A2 (en) * 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
CN101730041A (zh) 2009-06-26 2010-06-09 中兴通讯股份有限公司 一种基于用户当前所在时区的策略和计费控制方法及系统
EP2571882A1 (en) 2010-05-21 2013-03-27 Gilead Sciences, Inc. Heterocyclic flaviviridae virus inhibitors

Also Published As

Publication number Publication date
US20110190314A1 (en) 2011-08-04
MX2009006235A (es) 2009-06-22
WO2008073942A2 (en) 2008-06-19
CA2671683A1 (en) 2008-06-19
KR20090098884A (ko) 2009-09-17
US20080167286A1 (en) 2008-07-10
DOP2009000137A (es) 2009-06-30
EP2226074B1 (en) 2015-11-04
EP2101763B1 (en) 2012-07-18
AU2007333129A1 (en) 2008-06-19
CO6210820A2 (es) 2010-10-20
EP2226074A2 (en) 2010-09-08
US20160022658A1 (en) 2016-01-28
EP2226074A3 (en) 2011-03-09
ES2389116T3 (es) 2012-10-23
ECSP099495A (es) 2009-08-28
NO20092584L (no) 2009-09-14
ES2558054T3 (es) 2016-02-01
JP2010512419A (ja) 2010-04-22
US9186407B2 (en) 2015-11-17
BRPI0720124A2 (pt) 2014-03-04
EP2974727A1 (en) 2016-01-20
EP2101763A2 (en) 2009-09-23
WO2008073942A3 (en) 2008-12-04
TW200901995A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
CR10873A (es) Composiciones farmaceuticas y sus metodos de uso
UY30304A1 (es) Moduladores de mglur5 i
UY30308A1 (es) Moduladores de mglur5 v
UY30307A1 (es) Moduladores de mglur5 vi
UY30306A1 (es) Moduladores de mglur5 iii
MX2009001829A (es) Anticuerpo especifico prlr y sus usos.
EP2076202A4 (en) DENTAL ARTICLES, METHODS AND KITS WITH A COMPRESSIBLE MATERIAL
HN2010001059A (es) Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes.
JO3408B1 (ar) مركبات بترين سلفون اميد ثيازول و أوكسازول
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
CL2007001451A1 (es) Compuestos derivados de [1,2,3]-tiazol-4-ilmetoxilo, agonista del receptor farnesoide x (fxr); composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dislipidemia y enfermedades relacionadas.
UY30305A1 (es) Moduladores de mglur5 iv
BRPI0717442A2 (pt) Stent endovascular para liberação de droga e método de uso
FR2883179B1 (fr) Comprime enrobe
BRPI0922364A2 (pt) Composto, composição farmacêutica e uso de um composto
UA98299C2 (ru) Новая лекарственная форма рацекадотрила
UY30309A1 (es) Moduladores de mglur5 ii
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
ECSP088971A (es) Ligandos 101 de los receptores nicotínicos de acetilcolina
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
DK1923045T3 (da) Kosmetisk formulering indeholdende glucosylglycerider og pulverråstoffer
BRPI0914371A2 (pt) "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina